We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Four life sciences companies from across the UK will benefit from the first tranche of Life Sciences Innovative Manufacturing Fund (LSIMF) grants.
New specific guidance on dose-dependent prolongation of QTc with ondansetron.
Baxter Healthcare Limited has informed us that a quality defect has been identified with the above product where the front panel of a small number of infusion bags was found to be missing the red text.
Zoledronic acid is associated with reports of renal impairment and renal failure, especially in patients with pre-existing renal dysfunction or other risk factors. Renal function should be measured before each dose, and patients should be adequately hydrated before treatment. Renal...
Monitor serum phosphate levels in patients treated with multiple high-dose administrations, or those on long-term treatment, and in those with pre-existing risk factors for hypophosphataemia. Re-evaluate ferric carboxymaltose treatment in patients with persistent hypophosphataemia.
UKAEA and First Light Fusion to construct a new facility to house First Light’s new net energy gain demonstrator (“Machine 4”) in Oxford, UK.
UKAEA's Project Delivery Services Framework
Work also begins on biggest ever £100 million Project Gigabit contract to connect 60,000 rural homes and businesses in Cumbria, delivered by Fibrus
(Hospira) Use an alternative pump, where available. (MDA/2013/078)
DCMS Minister celebrates tech success, particularly in AI, throughout the UK and champions the sector during London Tech Week
New reports of serious hypersensitivity reactions (including anaphylaxis) in patients receiving panitumumab, some of which were fatal.
£11.3 million funding to help UK distilleries ditch fossil fuels and develop low carbon heating systems that will make production processes greener.
Employment Tribunal decision.
The authorised dose regimen for N-acetylcysteine (NAC) in paracetamol overdose is 3 consecutive bags given intravenously over 21 hours. Prescribing information is being updated to advise that continued treatment with NAC may be necessary depending on clinical evaluation of the...
While an urgent EU safety review evaluates reports of serious cardiovascular events and immune-mediated reactions, including autoimmune hepatitis, the use of alemtuzumab (Lemtrada) has been restricted and strengthened requirements have been introduced to monitor vital signs and liver function before...
Launch of the UK-Singapore Universities Alliance for Entrepreneurship and Innovation (UKSAEI)
Proof of concepts will be developed to further fusion energy
A review of the benefits and risks of alemtuzumab (including fatal reactions) in the treatment of multiple sclerosis has now concluded and recommended a revised indication, additional contraindications, and strengthened monitoring requirements before, during and after treatment. Patients offered alemtuzumab...
New £30 million funding grants to help farmers boost their businesses and add extra value to their produce.
Manufactured by CME (a BD company) – updated advice to address ‘wear and tear’ of the syringe pump motor block which may lead to under-infusion.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).